196 filings
Page 6 of 10
6-K
r69ns9vx
11 Jan 21
Entera Bio Issues Letter to Shareholders
8:30am
6-K
cfe7k1tb
10 Dec 20
Current report (foreign)
8:30am
6-K
di4erd
30 Nov 20
Entera Bio Appoints Spiros Jamas As Chief Executive Officer
4:05pm
6-K
jiq ctwv2zxasxl
19 Nov 20
Condensed Consolidated Interim Financial Statements
8:30am
6-K
jjxhpa8v4w9nigx8
19 Nov 20
Entera Bio LTD Announces Third Quarter 2020 Financial Results and Provides Clinical Update
6:30am
6-K
ec6 eocee6hdfpy9
9 Nov 20
Entera Bio LTD Announces Completion of Enrollment In Phase 2
8:30am
6-K
ofliuent62 llwbcbv
20 Aug 20
Condensed Consolidated Interim Financial Statements
6:32am
6-K
3gzcliz4rrhep
20 Aug 20
Entera Bio LTD Announces Interim Data from Phase 2 Clinical Trial of
6:30am
6-K
mk4ese9j
17 Aug 20
Entera Bio to Report Second Quarter 2020 Business and Financial
8:30am
6-K
hiyst caogs4i
10 Aug 20
Entera Bio Announces Management Changes
8:42am
6-K
bqjsho13v4cxsyv
5 Aug 20
Entera Bio to Present at Btig’s Virtual Biotechnology
8:30am
EFFECT
1u7e0 0yqv5m
23 Jul 20
Notice of effectiveness
12:15am
6-K
tn5wl
22 Jul 20
Entera Bio LTD Announces Highly Encouraging Oral PTH Market
4:00pm
CORRESP
lvxdyh1
20 Jul 20
Correspondence with SEC
12:00am
UPLOAD
56y3jsi4
17 Jul 20
Letter from SEC
12:00am
F-3
vle1 hommajcz0
13 Jul 20
Shelf registration (foreign)
5:28pm
6-K
crnrmn
7 Jul 20
Entera Bio LTD Provides Update on Phase 2 Clinical Trial of EB613
8:30am
6-K
h0ty iv7ssom
26 Jun 20
Current report (foreign)
7:00am
EFFECT
3pa7me1l1
25 Jun 20
Notice of effectiveness
12:15am
CORRESP
laha7a
22 Jun 20
Correspondence with SEC
12:00am